Essen

• The efficacy and the safety of two doses of CHF6001 for the treatment of Chronic Obstructive Pulmonary Disease (COPD) Ended
  2023-510175-60-00 5 2021-06-16 Chronic obstructive pulmonary disease (COPD) and Chronic Bronchitis
• An open-label, long-term, safety and tolerability study of SAR445088 in participants with cold agglutinin disease previously treated with SA … Ended
  2023-510210-68-00 3 2021-05-26 Autoimmune haemolytic anaemia
• CLL-Frail - A prospective, multicenter phase II trial of acalabrutinib in very old (≥80y) or frail CLL-Patients Ended
  2023-507002-14-00 4 2021-05-20 treatment-naïve or relapsed/refractory chronic lymphocytic leukemia
• Study of Ravulizumab in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN) Ended
  2023-507977-16-00 4 2021-05-10 Lupus Nephritis (LN) Immunoglobulin A Nephropathy (IgAN)
• A first-in-human clinical trial in adult patients with advanced non-small cell lung cancer of a personalised therapy targeting specific muta … Ended
  2024-513060-26-00 7 2021-04-07 Non-small cell lung cancer
• A study to investigate the novel agent BNT111 and cemiplimab in combination or as single agents in patients with advanced melanoma that has … Ended
  2023-509513-36-00 4 2021-03-24 Melanoma (Stage III and IV)
• Clinical Study of the Efficacy, Safety and Pharmacokinetics of Ustekinumab as Intravenous Induction Treatment Followed by Subcutaneous Ustek … Ended
  2023-504978-38-00 5 2021-03-16 Moderately to Severely Active Crohn's Disease
• A Clinical Study of the Efficacy, Safety and Pharmacokinetics of Ustekinumab as Intravenous Induction Treatment Followed by Subcutaneous Ust … Ended
  2023-504977-19-00 5 2021-03-15 Moderately to Severely Active Ulcerative Colitis
• A study to evaluate the effects of ALIS based treatment in patients newly diagnosed with nontuberculous mycobacterial lung infection caused … Ended
  2023-505273-33-00 5 2021-02-15 "Adult Subjects with Newly Diagnosed Nontuberculous Mycobacterial (NTM
• Study of efficacy and safety of LNP023 in primary IgA nephropathy patients. Ended
  2024-511067-29-00 5 2021-01-25 IgA Nephropathy
• Placebo-controlled Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants wit … Ended
  2023-508443-40-00 5 2020-12-18 Lung Cancer, Non-Small Cell
• Cognitive function after liver transplantation comparing Tacrolimus formulations Ended
  2024-513963-22-00 6 2020-12-09 ICD 10: Z94.4 Liver transplant status
• A study of Gilteritinib combined with chemotherapy to treat Children, Adolescents and Young Adults with Relapsed or Refractory Acute Myeloid … Ended
  2024-512469-15-00 9 2020-12-08 FMS-like Tyrosine Kinase 3 (FLT3)/Internal Tandem Duplication (ITD) Po
• Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor tolebrutinib (SAR442168) (PERSEUS) Ended
  2024-514495-41-00 5 2020-11-04 Primary Progressive Multiple Sclerosis
• Clinical safety study on 5-Aminolevulinic acid (5-ALA) in children and adolescents with brain tumors Ended
  2024-517575-20-00 4 2020-08-24 different types of brain tumors
• Two-Part Study for Dose Determination of Vesleteplirsen (SRP-5051) (Part A), Then Dose Efficacy (Part B) in Participants With Duchenne Muscu … Ended
  2023-509935-23-00 4 2020-08-21 Duchenne Muscular Dystrophy
• A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes (SURPASS-CV … Ended
  2023-507846-96-00 5 2020-06-19 Type 2 Diabetes Mellitus
• Phase-I/II trial for relapsed or refractory AML patients combining cytarabine and mitoxantrone with venetoclax (TUD-RELAX1-070) Ended
  2024-514018-12-00 9 2020-04-06 female and male adult patients with acute myeloid leukemia (AML) at fi
• CIRCULATE Ended
  2023-506715-18-00 5 2019-12-04 colon cancer stage II, rectal cancer stage II
• Neoadjuvant nivolumab combination treatment in resectable non-small cell lung cancer patients: Defining optimal combinations and determinant … Ended
  2024-513074-22-00 4 2019-12-02 non-small cell lung cancer (NSCLC) of clinical stages IB, II and selec
• A study of nivolumab and ipilimumab in untreated patients with stage 3 NSCLC that is unable or not planned to be removed by surgery Ended
  2022-502886-71-00 5 2019-11-20 Previously Untreated Locally Advanced Non-small Cell Lung Cancer (LA N
• Treatment with Acalabrutinib in patients with chronic lymphocytic leukemia Ended
  2023-507669-24-00 5 2019-11-05 Chronic lymphocytic leukemia
• Pembrolizumab or Placebo Plus Gemcitabine/Cisplatin for First-Line Advanced Ended
  2023-506657-38-00 5 2019-10-02 Biliary Tract Carcinoma
• Phase 3 study of pembrolizumab plus lenvatinib in endometrial carcinoma Ended
  2023-505614-17-00 5 2019-09-20 Participants with advanced or recurrent endometrial carcinoma

Showing 913–936 of 965 trials